Prion diseases are a group of neurodegenerative disorders characterized by the accumulation of misfolded prion protein (called PrPSc). Although conversion of the cellular prion protein (PrPC) to PrPSc is still not completely understood, most of the therapies developed until now are based on blocking this process. Here, we propose a new drug strategy aimed at clearing prions without any direct interaction with neither PrPC nor PrPSc. Starting from the recent discovery of SERPINA3/SerpinA3n upregulation during prion diseases, we have identified a small molecule, named compound 5 (ARN1468), inhibiting the function of these serpins and effectively reducing prion load in chronically infected cells. Although the low bioavailability of this compound does not allow in vivo studies in prion-infected mice, our strategy emerges as a novel and effective approach to the treatment of prion disease.

Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance / Colini Baldeschi, Arianna; Zattoni, Marco; Vanni, Silvia; Nikolic, Lea; Ferracin, Chiara; La Sala, Giuseppina; Summa, Maria; Bertorelli, Rosalia; Bertozzi, Sine Mandrup; Giachin, Gabriele; Carloni, Paolo; Bolognesi, Maria Laura; De Vivo, Marco; Legname, Giuseppe. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 1520-4804. - 65:13(2022), pp. 8998-9010. [10.1021/acs.jmedchem.2c00205]

Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance

Colini Baldeschi, Arianna;Zattoni, Marco;Vanni, Silvia;Nikolic, Lea;Ferracin, Chiara;Giachin, Gabriele;Carloni, Paolo;Bolognesi, Maria Laura;Legname, Giuseppe
2022-01-01

Abstract

Prion diseases are a group of neurodegenerative disorders characterized by the accumulation of misfolded prion protein (called PrPSc). Although conversion of the cellular prion protein (PrPC) to PrPSc is still not completely understood, most of the therapies developed until now are based on blocking this process. Here, we propose a new drug strategy aimed at clearing prions without any direct interaction with neither PrPC nor PrPSc. Starting from the recent discovery of SERPINA3/SerpinA3n upregulation during prion diseases, we have identified a small molecule, named compound 5 (ARN1468), inhibiting the function of these serpins and effectively reducing prion load in chronically infected cells. Although the low bioavailability of this compound does not allow in vivo studies in prion-infected mice, our strategy emerges as a novel and effective approach to the treatment of prion disease.
2022
65
13
8998
9010
https://doi.org/10.1021/acs.jmedchem.2c00205
Colini Baldeschi, Arianna; Zattoni, Marco; Vanni, Silvia; Nikolic, Lea; Ferracin, Chiara; La Sala, Giuseppina; Summa, Maria; Bertorelli, Rosalia; Bert...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11767/133936
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact